Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 1/20 | 0.39 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MTHFD2 | P13995 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7909047 | 0.90 | TNKS (0.37) | TNKSTNKS2KMT2A | |
| SCHEMBL7913668 | 0.90 | TNKS (0.37) | TNKSTNKS2KMT2A | |
| SCHEMBL7898135 | 0.86 | AURKB (0.41) | AURKBENPP2KMT2APARP1TRAP1 | |
| SCHEMBL7905815 | 0.82 | TRAP1 (0.39) | TRAP1 | |
| SCHEMBL1721897 | 0.82 | PDE9A (0.40) | TNKSTNKS2TRAP1ALDH1A1HPGD | |
| SCHEMBL1722000 | 0.81 | KDM4E (0.39) | AURKBPARP1TRAP1KDM4EMAPK14 | |
| SCHEMBL7909018 | 0.81 | GRIN2D (0.51) | AURKBKMT2APARP1TRAP1KDM4E | |
| SCHEMBL1721772 | 0.79 | HDAC6 (0.43) | KMT2AKDM4ESMN1; SMN2POLBALDH1A1 | |
| SCHEMBL7904511 | 0.79 | AKT1 (0.40) | — | |
| SCHEMBL7908673 | 0.78 | PDE9A (0.47) | TNKSTNKS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130085134-A1 | QUINOXALINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-04-04 | — | — | US | disclosed |
| US-20130085134-A1 | QUINOXALINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-04-04 | — | — | US | disclosed |
| US-8357688-B2 | Substituted imidazo[1,5-a]quinoxalin-4(5H)-ones as PDE9 inhibitors | ASTELLAS PHARMA INC. (JP) | 2013-01-22 | — | — | US | disclosed |
| US-8357688-B2 | Substituted imidazo[1,5-a]quinoxalin-4(5H)-ones as PDE9 inhibitors | ASTELLAS PHARMA INC. (JP) | 2013-01-22 | — | — | US | disclosed |
| US-20110319385-A1 | QUINOXALINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-12-29 | — | — | US | disclosed |
| US-20110319385-A1 | QUINOXALINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-12-29 | — | — | US | disclosed |
| WO-2010101230-A1 | QUINOXALINE COMPOUNDS | アステラス製薬株式会社 (JP) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085134-A1 | QUINOXALINE COMPOUND | PDE9A, PDE2A, PDE3A | TNKS 2743/4885TNKS2 2948/4885AURKB 4313/4885 |
| US-20110319385-A1 | QUINOXALINE COMPOUND | PDE9A, PDE5A, PDE3A | TNKS 1273/4885TNKS2 1647/4885AURKB 4294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.